Loading clinical trials...
Loading clinical trials...
A Non-randomized, Open-label Dose-finding Trial of Combined Cytotoxic and Immune-Stimulatory Strategy for the Treatment of Resectable Primary Malignant Glioma
Conditions
Interventions
Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L
Locations
1
United States
University of Michigan Health System Department of Neurosurgery
Ann Arbor, Michigan, United States
Start Date
April 1, 2014
Primary Completion Date
February 1, 2019
Completion Date
January 1, 2021
Last Updated
September 19, 2024
NCT05099003
NCT05839379
NCT00083512
NCT07100730
NCT05281731
NCT07391215
Lead Sponsor
University of Michigan Rogel Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions